Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
PhD Student in Health Education and Promotion, Social Determinants in Health Promotion Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Ethiop J Health Sci. 2022 Jul;32(4):849-864. doi: 10.4314/ejhs.v32i4.23.
Pregnancy is a major concern among women with the sickle cell disease (SCD), and it is associated with increased adverse outcomes. The aim of the present meta-analysis is to report the fetomaternal outcomes in different sickle cell genotypes.
In this systematic review and meta-analysis, a comprehensive search of databases and search engines such as PubMed, Scopus, Web of Science, ProQuest, Cochrane Library, Science Direct and Google Scholar were performed. Any observational studies that had compared at least one outcome such as maternal outcomes, fetal outcomes, and morbidity between two groups of pregnant women with different types of sickle cell genotypes and pregnant women without SCD were evaluated.
A total number of 9,827 pregnant women with SCD were examined. The results showed that pregnancy in SCD increased the risk of adverse outcomes for the mothers (including postpartum hemorrhage, prematurity, pregnancy-induced hypertension, pre-eclampsia, eclampsia, cesarean section, lower segment cesareansection, maternal death), fetus (including live births, low birth weight, intrauterine growth restriction, APGAR score at 5 min <7, stillbirth, neonatal death, perinatal mortality, acute fetal distress, intrauterine fetal death) and morbidity among the SCD(severe anemia, urinary tract infection, blood transfusion, painful crisis, acute chest syndrome, vaso-occlusive crises).
According to the results of this meta-analysis, pregnancy in the SCD is associated with an increased risk of maternal outcomes, fetal outcomes, and morbidity among SCD patients with different genotypes. Pregnancy in sickle cell hemoglobinopathies needs careful multidisciplinary management and cautious caring so as to decrease maternal and fetal morbidity and mortality.
妊娠是镰状细胞病(SCD)女性的主要关注点,并且与不良结局的增加有关。本荟萃分析的目的是报告不同镰状细胞基因型的母婴结局。
在本系统评价和荟萃分析中,全面搜索了数据库和搜索引擎,如 PubMed、Scopus、Web of Science、ProQuest、Cochrane Library、Science Direct 和 Google Scholar。评估了任何比较至少一种结局(如母亲结局、胎儿结局和发病率)的观察性研究,这些结局在两组不同类型的镰状细胞基因型的孕妇和没有 SCD 的孕妇之间。
共检查了 9827 名患有 SCD 的孕妇。结果表明,SCD 妊娠增加了母亲(包括产后出血、早产、妊娠高血压、先兆子痫、子痫、剖宫产、下段剖宫产、母亲死亡)、胎儿(包括活产、低出生体重、宫内生长受限、APGAR 评分 5 分钟<7、死产、新生儿死亡、围产儿死亡率、急性胎儿窘迫、宫内胎儿死亡)和发病率的不良结局风险在 SCD(严重贫血、尿路感染、输血、疼痛危机、急性胸部综合征、血管阻塞性危机)中。
根据这项荟萃分析的结果,SCD 妊娠与不同基因型 SCD 患者的母亲结局、胎儿结局和发病率增加有关。镰状细胞血红蛋白病的妊娠需要仔细的多学科管理和谨慎的护理,以降低母婴发病率和死亡率。